L. Parents-de-guillaume-divorcent-en-février, Le père 48 ans, est chauffeur poids lourds, la mère 43 ans, 1991.

. En-octobre, Le début des troubles semble remonter au week-end précédant son hospitalisation, marqué par des bizarreries (Guillaume voulait laisser ses baguettes de tambour chez le boulanger) Le médecin traitant a été appelé. Ce dernier prescrit des neuroleptiques mais Guillaume refuse. Le lendemain, devant l'importance des troubles, 1991.

C. Demily and N. Franck, Schizophrénie: diagnostic et prise en charge. Issy-les-Moulineaux, 2013.

F. Rouillon, ??pid??miologie des troubles psychiatriques, Annales M??dico-psychologiques, revue psychiatrique, vol.166, issue.1, pp.63-70, 2008.
DOI : 10.1016/j.amp.2007.11.010

S. Kescskémeti and . Schizophrénie-débutante, In: Manuel de psychiatrie clinique et psychopathologique de l'adulte. puf. Paris; 2012, pp.459-73

A. Mortimer, P. Singh, C. Shepherd, and J. Puthiryackal, Clozapine for Treatment-Resistant Schizophrenia: National Institute of Clinical Excellence (NICE) Guidance in the Real World, Clinical Schizophrenia & Related Psychoses, vol.4, issue.1, pp.49-55, 2010.
DOI : 10.3371/CSRP.4.1.4

J. Kane, G. Honigfeld, and H. Meltzer, Clozapine for the Treatment-Resistant Schizophrenic, Archives of General Psychiatry, vol.45, issue.9, pp.789-96, 1988.
DOI : 10.1001/archpsyc.1988.01800330013001

J. Tiihonen, J. Haukka, M. Taylor, P. Haddad, M. Patel et al., A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia, American Journal of Psychiatry, vol.168, issue.6, pp.603-612, 2011.
DOI : 10.1176/appi.ajp.2011.10081224

T. Barnes, Evidencs-based guidelines for the pharmacological treatment of schizophrénia: recommandations from the British association for psychopharmacology, J Psychopharmacol, issue.25, pp.567-620, 2011.

É. Weltgesundheitsorganisation, Classification internationale des maladies, dixième révision, chapitre V (F): Troubles mentaux et troubles du comportement, Descriptions cliniques et directives pour le diagnostic, 1993.

V. Kapsambelis and F. Laugier, Manuel de psychiatrie clinique et psychopathologique de l'adulte. Paris: Puf, 2012.

P. Nguimfack, ??valuation de la notion de ????schizophr??nie r??sistante????. Aspects pharmacologiques et incidences des nouveaux antipsychotiques, Annales M??dico-psychologiques, revue psychiatrique, vol.162, issue.6, pp.441-52, 2004.
DOI : 10.1016/j.amp.2003.10.020

C. Bardenat and J. Sutter, Un cas de résistance à l'insuline dans le traitement de la schizophrénie. Congrès des aliénistes, pp.346-349, 1938.

M. Bleuer, The long-term course of the schizophrenic psychoses, Psychol Med, vol.4, pp.244-54, 1974.

M. Ciompi and C. Müller, L'évolution des schizophrénies, Evol Psy, vol.7, pp.1219-1262, 1977.

T. Itill, A. Keskiner, and F. M. , Therapeutic studies in ???therapy resistant??? schizophrenic patients, Comprehensive Psychiatry, vol.7, issue.6, pp.488-93, 1996.
DOI : 10.1016/S0010-440X(66)80028-7

P. Deniker, H. Loo, and M. Cottereau, Parental loxapine severely disturbed schizophrenic patients, J Clin Psychiatry, vol.41, issue.1, pp.23-29, 1980.

J. Kane, factor which can make patients difficult to treat, Schizophr Bull, vol.12, issue.31, pp.261-76, 1996.

M. Maurice, Association de la clozapine à d'autres antipsychotiques atypiques dans le cadre de la prise en charge de la schizophrénie résistante [Thèse d'exercice], 2013.

J. Vanelle, Notion de schizophrénie résistante, pp.13-21, 1995.

R. Conelley and D. Kelly, Management of treatment resistance in schizophrenia, Biological Psychiatry, vol.50, issue.11, pp.898-911, 2001.
DOI : 10.1016/S0006-3223(01)01271-9

T. Suzuki, R. G. Mulsant, and B. , Treatment resistant schizophrenia and response to antipsychotics: A review, Schizophrenia Research, vol.133, issue.1-3, pp.54-62, 2011.
DOI : 10.1016/j.schres.2011.09.016

A. Lehman, J. Lieberman, and L. Dixon, Practice guideline for the treatment of patients with schizophrenia, second edition, Am J Psychiatry, vol.161, issue.2, pp.1-56, 2004.

T. Moore, R. Buchanan, P. Buckley, J. Chiles, R. Conley et al., The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia, The Journal of Clinical Psychiatry, vol.68, issue.11, pp.1751-62, 2007.
DOI : 10.4088/JCP.v68n1115

H. Autorité and D. Santé, Commission de la transparence Avis du 30 novembre 2011. antipsychotiques de seconde génération, 2016.

R. Buchanan, J. Kreyenbuhl, D. Kelly, J. Noel, D. Boggs et al., The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, Schizophrenia Bulletin, vol.36, issue.1, pp.71-93, 2010.
DOI : 10.1093/schbul/sbp116

A. Hasan, P. Falkai, and T. Wobrock, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance, The World Journal of Biological Psychiatry, vol.22, issue.1, pp.318-78, 2012.
DOI : 10.1016/j.schres.2007.02.009

I. Barofsky, Compliance, adherence and the therapeutic alliance: steps in the development of self-care, Soc Sci & Med, vol.12, pp.369-76, 1978.

I. De-beauchamp, D. Lévy-chavagnat, and J. Chavagnat, ??ducation th??rapeutique et schizophr??nie??: Quels buts???, Actualit??s Pharmaceutiques, vol.52, issue.524, pp.8-13, 2013.
DOI : 10.1016/j.actpha.2012.12.023

E. Corruble and P. Hardy, Observance du traitement en psychiatrie, EMC - Psychiatrie, vol.1, issue.1, 2003.
DOI : 10.1016/S0246-1072(03)00114-7

N. Baup and F. Mouaffak, Schizophrénie résistante et ultra-résistante, Séminaire de Psychiatrie Biologique, vol.38, pp.161-81, 2008.

C. Billiet, P. Antoine, R. Lesage, and M. Sangare, Insight et interventions psycho??ducationnelles dans la schizophr??nie, Annales M??dico-psychologiques, revue psychiatrique, vol.167, issue.10, pp.745-52, 2009.
DOI : 10.1016/j.amp.2008.04.007

J. Kane, Abstract, CNS Spectrums, vol.49, issue.S17, pp.21-27, 2007.
DOI : 10.4088/JCP.v66n0806

G. Hunt, J. Bergen, and M. Bashir, Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse, Schizophrenia Research, vol.54, issue.3, pp.253-64, 2002.
DOI : 10.1016/S0920-9964(01)00261-4

E. Khantzian, The Self-Medication Hypothesis of Addictive Disorders: Focus on Heroin and Cocaine Dependence, Am J Pscychiatry, vol.142, issue.11, pp.1259-64, 1985.
DOI : 10.1007/978-1-4613-1837-8_7

E. Khantzian, The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration and Recent Applications, Harvard Review of Psychiatry, vol.4, issue.5, pp.231-275, 1997.
DOI : 10.3109/10673229709030550

S. Potvin, E. Stip, and J. Roy, Schizophrenia and Cannabinoids, Drogues, sant?? et soci??t??, vol.2, issue.2, 2004.
DOI : 10.7202/008536ar

P. Robert, P. Benoit, and S. Gueniffey, Evolution des psychoses: résultats d'une enquête clinique portant sur 383 cas suivi pendant dix ans (1975-1985), Ann Med Psychol, issue.1, pp.15-32, 1989.

G. Chouinard, B. Jones, and L. Annable, Neuroleptic induced supersensitivity psychosis, Am J Psych, vol.135, pp.1409-1419, 1978.

H. Hippius, A historical perspective of clozapine, pp.22-25, 1990.

L. Pharmacocinétique, In : médicaments antipsychotiques, évolution ou révolution ?, Olié J.P., Daléry J., Azorin J.M., Paris. Acanthe, pp.171-188, 2001.

M. Stephen and . Stahl, Psychopharmacologie essentielle. 2002 e éd Paris: Flammarion, pp.431-433

M. Monville, La clozapine: de la théorie à la pratique [Internet], Disponible sur, 1982.

B. Rouleau, P. Vincent, and J. Martel, Le monitorage thérapeutique de la clozapine : une nécessité clinique, Pharmactuel, vol.41, issue.2, pp.87-93, 2008.

N. Mckinnon, A. Azad, and B. Waters, Clozapine-induced bowel infarction: a case report, Psychiatry (Edgmont), vol.3, pp.30-35, 2009.

V. Shah and J. Anderson, Clozapine-induced ischaemic colitis, Case Reports, vol.2013, issue.jan22 1, 2013.
DOI : 10.1136/bcr-2012-007933

P. Llis, R. Mclean, and H. Harrison-woolrych, Clozapine: fatal 'constipation' more common than fatal granulocytosis. New Zealand Medicines and Medical Devices Safety Authority, Prescriber Update, vol.28, 2007.

I. Paul, V. Basavaraju, J. Narayanaswamy, and S. Math, Clozapine-induced pericarditis: an overlooked adverse effect, Clin Schizophr Relat Psychoses. oct, vol.8, issue.3, pp.133-137, 2014.

. Pons, A. Villanueva, A. Romero, J. Goti, E. Fernandez-egea et al., Should obesity be a limiting factor for clozapine treatment? Rev Psiquiatr Salud Ment, juin, vol.6, issue.2, pp.75-84, 2013.

R. Parekh, Z. Fattah, D. Sahota, and B. Colaco, Clozapine induced tubulointerstitial nephritis in a patient with paranoid schizophrenia, Case Reports, vol.68, issue.may20 1, 2014.
DOI : 10.1136/bcr-2013-203502

S. Grover and S. Sahoo, Clozapine induced akathisia: A case report and review of the evidence, Indian Journal of Pharmacology, vol.47, issue.2, pp.234-239, 2015.
DOI : 10.4103/0253-7613.153441

S. Porcelli, B. Balzarro, and A. Serretti, Clozapine resistance: Augmentation strategies, European Neuropsychopharmacology, vol.22, issue.3, pp.165-82, 2012.
DOI : 10.1016/j.euroneuro.2011.08.005

I. Sommer, M. Begemann, A. Temmerman, and S. Leucht, Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review, Schizophrenia Bulletin, vol.38, issue.5, 2011.
DOI : 10.1093/schbul/sbr004

J. Chang, Y. Ahn, and H. Park, Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory Schizophrenia, The Journal of Clinical Psychiatry, vol.69, issue.5, pp.720-731, 2008.
DOI : 10.4088/JCP.v69n0505

W. Fleischhacker, M. Heikkinen, and J. Olie, Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial, The International Journal of Neuropsychopharmacology, vol.13, issue.08, pp.1115-1125, 2010.
DOI : 10.1017/S1461145710000490

M. Muscatello, A. Bruno, and G. Pandolfo, Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study, Schizophrenia Research, vol.127, issue.1-3, pp.93-99, 2011.
DOI : 10.1016/j.schres.2010.12.011

J. Munro, P. Matthiasson, and S. Osborne, Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine, Acta Psychiatrica Scandinavica, vol.173, issue.44, pp.292-300, 2004.
DOI : 10.1001/archpsyc.60.6.553

R. Shiloh, Z. Zemishlany, and D. Aizenberg, Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study, The British Journal of Psychiatry, vol.171, issue.6
DOI : 10.1192/bjp.171.6.569

J. Wang, I. Omori, M. Fenton, and B. Soares, Sulpiride Augmentation for Schizophrenia, Schizophrenia Bulletin, vol.36, issue.2, 2010.
DOI : 10.1093/schbul/sbp163

R. Rajarethinam, S. Gilani, M. Tancer, and J. Dequardo, Augmentation of clozapine partial responders with conventional antipsychotics, Schizophrenia Research, vol.60, issue.1, pp.97-98, 2003.
DOI : 10.1016/S0920-9964(02)00293-1

N. Mossaheb, J. Sacher, and G. Wiesegger, P.3.c.037 Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia, European Neuropsychopharmacology, vol.16, p.416, 2006.
DOI : 10.1016/S0924-977X(06)70524-7

C. Rummel-kluge, K. Komossa, S. Schwarz, H. Hunger, F. Schmid et al., Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis, Schizophrenia Research, vol.123, issue.2-3, pp.225-233, 2010.
DOI : 10.1016/j.schres.2010.07.012

J. Tiihonen, P. Halonen, K. Wahlbeck, E. Repo-tiihonen, S. Hyvarinen et al., Topiramate Add-On in Treatment-Resistant Schizophrenia, The Journal of Clinical Psychiatry, vol.66, issue.08, pp.66-1012, 2005.
DOI : 10.4088/JCP.v66n0808

D. Kelly, R. Conley, S. Feldman, Y. Yu, R. Mcmahon et al., Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia, Psychiatric Quarterly, vol.152, issue.2, pp.77-81, 2006.
DOI : 10.1007/s11126-006-7963-9

M. Lu, H. Lane, K. Chen, M. Jann, M. Su et al., Fluvoxamine Reduces the Clozapine Dosage Needed in Refractory Schizophrenic Patients, The Journal of Clinical Psychiatry, vol.61, issue.8, pp.61-594, 2000.
DOI : 10.4088/JCP.v61n0809

H. Silver, M. Kushnir, and A. Kaplan, Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study, Biological Psychiatry, vol.40, issue.7, pp.671-674, 1996.
DOI : 10.1016/0006-3223(96)00170-9

R. Buchanan, B. Kirkpatrick, N. Bryant, P. Ball, and A. Breier, Fluoxetine augmentation of clozapine treatment in patients with schizophrenia, Am. J. Psychiatry, vol.153, pp.1625-1627, 1996.

J. Crilly, The history of clozapine and its emergence in the US market: a review and analysis, History of Psychiatry, vol.18, issue.1, pp.39-60, 2007.
DOI : 10.1177/0957154X07070335

A. Sharma and S. Grover, Delay in starting clozapine and treatment guidelines, Br J Psychiatry J Ment Sci. févr, vol.202, pp.154-159, 2013.

O. Howes, F. Vergunst, S. Gee, P. Mcguire, S. Kapur et al., Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation, The British Journal of Psychiatry, vol.201, issue.6, pp.481-486, 2012.
DOI : 10.1192/bjp.bp.111.105833

K. Xenitidis, C. Campbell, and A. Mortimer, Identifying treatment-resistant schizophrenia, The British Journal of Psychiatry, vol.202, issue.3, p.238, 2013.
DOI : 10.1192/bjp.202.3.238

M. Patel, Clinician hesitation prior to clozapine initiation: is it justifiable?, The British Journal of Psychiatry, vol.201, issue.6, pp.425-432, 2012.
DOI : 10.1192/bjp.bp.112.114777

J. Nielson, M. Dahm, H. Lublin, and D. Taylor, Psychiatrists??? attitude towards and knowledge of clozapine treatment, Journal of Psychopharmacology, vol.93, issue.1, pp.965-71, 2010.
DOI : 10.1177/0269881108100320

L. Best-shaw, J. Nagar, A. David, D. Rose, and M. Patel, Psychiatrists' perspectives regarding antipsychosis: Dose choice and plasma level drug monitoring, J Psychopharmacol, vol.26, issue.A39, 2012.

G. Remington, O. Agid, G. Foussias, M. Hahn, N. Rao et al., Clozapine???s Role in the Treatment of First-Episode Schizophrenia, American Journal of Psychiatry, vol.170, issue.2, pp.146-51, 2013.
DOI : 10.1176/appi.ajp.2012.12060778

R. Girgis, M. Phillips, X. Li, K. Li, H. Jiang et al., Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial, The British Journal of Psychiatry, vol.199, issue.4, pp.281-288, 2011.
DOI : 10.1192/bjp.bp.110.081471

C. Charpin, J. Meynard, R. Bernadet, M. Sanchez, and D. Modavi, Historique de la sismothérapie, synapse, vol.137, pp.29-30, 1997.

R. Weiner, The Practice of Electroconvulsive Therapy Recommandation for treatment, training and Privileging: A Task Force report of the AmericanPsychiatric Association, American Psychiatric Association, 2001.

T. Pawe?czyk, ?. Ko?odziej, E. Kowalska, A. Pawe?czyk, and J. Rabe-jab?o?ska, Effectiveness and clinical predictors of response to combined ECT and antipsychotic therapy in patients with treatment-resistant schizophrenia and dominant negative symptoms, Psychiatry Research, vol.220, issue.1-2, pp.175-80, 2014.
DOI : 10.1016/j.psychres.2014.07.071

D. Ravanic, M. Draskovic, S. Dejanovic, D. Petrovic, M. Jovanovic et al., Efficacy of Different Antipsyhotics in Combination with ECT in Resistant Schizophrenia, European Psychiatry, vol.30, p.1622, 2015.
DOI : 10.1016/S0924-9338(15)31252-9

H. Hustig and R. Onilov, ECT rekindles pharmacological response in schizophrenia, European Psychiatry, vol.24, issue.8, pp.521-526, 2009.
DOI : 10.1016/j.eurpsy.2009.04.005

M. Majeske and C. Kellner, Consider ECT for Treatment-Resistant Childhood Schizophrenia, American Journal of Psychiatry, vol.171, issue.9, p.1000, 2014.
DOI : 10.1176/appi.ajp.2014.14050628

D. Driver, A. Anvari, C. Peroutka, R. Kataria, J. Overman et al., Management of Clozapine-Induced Fever in a Child, American Journal of Psychiatry, vol.171, issue.4, pp.398-402, 2014.
DOI : 10.1176/appi.ajp.2013.13070866

Y. Bloch, D. Stein, and G. Walter, ECT for schizophrenia spectrum disorder, in Electroconvulsive Therapy in Children and Adolescents. 2013 e éd, pp.191-216

H. Fablet-vergnaux, J. Loirat, and J. Vanelle, La place de l?????lectroconvulsivoth??rapie dans le traitement des schizophr??nes, Annales M??dico-psychologiques, revue psychiatrique, vol.161, issue.8, pp.603-611, 2003.
DOI : 10.1016/j.amp.2003.08.003

D. Carvalho, W. Olié, and J. , Electroconvulsivothérapie, publié par le congrès de psychiatrie et de neurologie de Langue française, Masson, vol.192, 2001.

E. Shimizu, M. Imai, M. Fujisaki, N. Shinoda, S. Handa et al., Maintenance electroconvulsive therapy (ECT) for treatment-resistant disorganized schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.31, issue.2, pp.571-574, 2007.
DOI : 10.1016/j.pnpbp.2006.11.014

G. Tuer, Efficacity and Safety of electroconvulsive therapy in deprssive disorders: a systematic review and meta-analysis, Lancet, issue.361, pp.799-808, 2003.

C. Datto, Side effects of electroconvulsive therapy, Depression and Anxiety, vol.150, issue.3, pp.130-134, 2000.
DOI : 10.1002/1520-6394(2000)12:3<130::AID-DA4>3.0.CO;2-C

M. Vamos, The Cognitive Side Effects of Modern ECT, The Journal of ECT, vol.24, issue.1, pp.18-24, 2008.
DOI : 10.1097/YCT.0b013e31815d9611

C. Goldman, Toward a definition of pychoeducation, Hosp and Comm Psych, vol.39, pp.666-673, 1988.

G. Deleu and O. Chambon, Thérapie psychoéducative familiale et psychoses chroniques Charleroi: Socrate, 1999.

F. Petitjean, Les effets de la psycho??ducation, Annales M??dico-psychologiques, revue psychiatrique, vol.169, issue.3, pp.184-191, 2011.
DOI : 10.1016/j.amp.2011.02.011

G. Hogarty, C. Anderson, and D. Reiss, Family Psychoeducation, Social Skills Training, and Maintenance Chemotherapy in the Aftercare Treatment of Schizophrenia, Archives of General Psychiatry, vol.48, issue.4, pp.340-347, 1991.
DOI : 10.1001/archpsyc.1991.01810280056008

B. Lachaux and F. Caroli, L'information : entre dire pour se protéger et informer pour permettre, Encéphale, vol.27, issue.NS1, pp.26-39, 2001.

F. Salomé, C. Lagathu, J. Demant, and F. Petitjean, Un programme d???information sur la maladie et ses traitements destin?? aux patients atteints de schizophr??nie??: P.A.C.T.??, Annales M??dico-psychologiques, revue psychiatrique, vol.160, issue.5-6, pp.416-436, 2002.
DOI : 10.1016/S0003-4487(02)00189-0

M. Castillo, I. Urdapilleta, F. Petitjean, J. Seznec, and D. Januel, L???annonce du diagnostic de schizophr??nie. Analyse textuelle d???entretiens cliniques, Annales M??dico-psychologiques, revue psychiatrique, vol.166, issue.8, pp.599-605, 2008.
DOI : 10.1016/j.amp.2006.04.011

D. Beauchamp, I. Giraud-baro, E. Bougerol, T. Calop, J. Allenet et al., Education th??rapeutique des patients psychotiques : impact sur la r??-hospitalisation, Education Th??rapeutique du Patient - Therapeutic Patient Education, vol.2, issue.2, pp.125-156, 2010.
DOI : 10.1051/tpe/2010014

C. Bonsack, S. Rexhaj, and J. Favrod, Psychoéducation: définition, historique, intérêt et limites In: Annales Médico-psychologiques, revue psychiatrique

S. Abbadi, Psychoéducation et schizophrénie : aléas d'une propédeutique. L'Information Psychiatrique, pp.81-709, 2005.

Y. Hodé, Prise en charge des familles de patients schizophr??nes, Annales M??dico-psychologiques, revue psychiatrique, vol.169, issue.3, pp.196-205, 2011.
DOI : 10.1016/j.amp.2011.02.015